The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Open accessAbstract
The cognitive hallmark of early Alzheimer's disease (AD) is an extraordinary inability to form new memories. For many years, this dementia was attributed to nerve-cell death induced by deposits of fibrillar amyloid beta (Abeta). A newer hypothesis has emerged, however, in which early memory loss is considered a synapse failure caused by soluble Abeta oligomers. Such oligomers rapidly block long-term potentiation, a classic experimental paradigm for synaptic plasticity, and they are strikingly elevated in AD brain tissue and transgenic-mouse AD models. The current work characterizes the manner in which Abeta oligomers attack neurons. Antibodies raised against synthetic oligomers applied to AD brain sections were found to give diffuse stain around neuronal cell bodies, suggestive of a dendritic pattern, whereas soluble brain extracts showed robust AD-dependent reactivity in dot immunoblots. Antigens in unfractionated AD extracts attached with specificity to cultured rat hippocampal neurons, binding within dendritic arbors at discrete puncta. Crude fractionation showed ligand size to be between 10 and 100 kDa. Synthetic Abeta oligomers of the same size gave identical punctate binding, which was highly selective for particular neurons. Image analysis by confocal double-label immunofluorescence established that >90% of the punctate oligomer binding sites colocalized with the synaptic marker PSD-95 (postsynaptic density protein 95). Synaptic binding was accompanied by ectopic induction of Arc, a synaptic immediate-early gene, the overexpression of which has been linked to dysfunctional learning. Results suggest the hypothesis that targeting and functional disruption of particular synapses by Abeta oligomers may provide a molecular basis for the specific loss of memory function in early AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite ongoing debate, Aβ accumulation, whether in the form of insoluble plaques, or smaller soluble oligomers does appear to be a primary driver of the disease process, particularly linked to synapse dysfunction [3].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, overexpression of APP and its proteolytic product, Aβ, have been implicated in the synaptic losses seen early in the development of AD [27].”
From FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein (2007) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other suggested Aβ binding partners at synapses include the α7-nicotinic receptor [49], Ephrin A4 [73], PSD95 [35, 50, 52] and LilrB2 [32].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [35]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“As previously discussed, amyloid-β oligomers bind to synapses [144] and interfere with the normal process of neurotransmission, long-term potentiation, and thereby memory formation [145].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [144]
In the citing paper
“Immunohistochemistry confirms that oligomers associate with neurons, accumulating very early in disease progression (Lacor et al., 2004), in loci distinct from amyloid deposits (Kayed et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“as have the related predictions that oligomers cause dysfunctional trafficking of ionotropic glutamate receptors and metabotropic glutamate receptors (Gong et al., 2003; Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“The possible source of extracellular oligomers and how they interact with neurons in human brain are suggested by their peri-somatic localization, observed in early-stage disease (Figure 1, left; (Lacor et al., 2004)).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“The same binding specificity and punctate pattern is observed for synthetic oligomers, particularly those greater than 50 kDa (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Oligomers show > 90% co-localization with the post-synaptic marker PSD-95 (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“This prediction was first confirmed for NMDA-Rs (Lacor et al., 2004; Lacor et al., 2007; Snyder et al., 2005).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“One rapid consequence is an aberrant expression of Arc (Activity-Regulated Cytoskeletal associated protein; (Lacor et al., 2004)).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Because Arc is an actin binding protein, its aberrant expression was predicted to disrupt receptor trafficking (Lacor et al., 2004), which could consequently disrupt plasticity (Gong et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Coupled with the potential of dendrites for activity-stimulated exocytosis (Kennedy et al., 2010), such a phenomenon could account for the “perineuronal deposits” of oligomers seen in Figure 1 (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“All of these processes are affected by Aβ oligomers in vitro, using primary neuronal cultures (12, 15, 36, 37).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [37]
In the citing paper
“Furthermore, extracellular Aβ1-42 oligomers preferentially target synapses when added to neurons [43, 91].”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [91]
In the citing paper
“Other binding partners that have been suggested to bind Aβ include the α7-nicotinic receptor [49], Ephrin A4 (EphA4) [73], PSD95 [35, 50, 52] or LilrB2 [32].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citationPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Flagged first, then by citations
Research works printed but not linked: 2
- Klein WL (2004) Cytotoxic intermediates in the fibrillation pathway: Aβ oligomers in Alzheimer's disease as a case study. In: Protein misfolding, aggregation and conformational diseases (Uversky V, ed). New York: Kluwer Academic/Plenum, in press.
- 2002, Nat Rev Neurosci, 3, 824
Cited by
Sorted by citations
Items 101–200 of 949
Arc/Arg3.1 Regulates an Endosomal Pathway Essential for Activity-Dependent β-Amyloid Generation
Wu, J., Petralia, R. S., Kurushima, H., Patel, H., Jung, M., Volk, L. J., Chowdhury, S., Shepherd, J. D., Dehoff, M. H., Li, Y., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.036 · Cited by 221
de Godoy, M. A., Saraiva, L. M., de Carvalho, L. R. P., Vasconcelos-dos-Santos, A., Beiral, H. J. V., Ramos, A. B., Silva, L. R. D. P., Leal, R. B., Monteiro, V. H. S., Braga, C. V., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.807180 · Cited by 214
Behavioral assays with mouse models of Alzheimer's disease: Practical considerations and guidelines
Puzzo, D., Lee, L. S., Palmeri, A., Calabrese, G., & Arancio, O. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.011 · Cited by 226
Clarke, J. R., Lyra e Silva, N. M., Figueiredo, C. P., Frozza, R. L., Ledo, J. H., Beckman, D., Katashima, C. K., Razolli, D., Carvalho, B. M., Frazão, R., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404183 · Cited by 214
Self-citationHong, S., Ostaszewski, B. L., Yang, T., O’Malley, T. T., Jin, M., Yanagisawa, K., Li, S., Bartels, T., & Selkoe, D. J. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.027 · Cited by 213
Malaplate, C., Florent‐Béchard, S., Youssef, I., Koziel, V., Sponne, I., Kriem, B., Leininger‐Muller, B., Olivier, J. L., Oster, T., & Pillot, T. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.02.010 · Cited by 224
Cell number changes in Alzheimer's disease relate to dementia, not to plaques and tangles
Andrade-Moraes, C. H., de Oliveira-Pinto, A. V., Castro-Fonseca, E., da Silva, C. G., Guimarães, D. M., Szczupak, D., Parente-Bruno, D. R., Carvalho, L. R. B., Polichiso, L., Valério‐Gomes, B., et al. (2013) · Brain · doi:10.1093/brain/awt273 · Cited by 223
Molecular reorganization of endocannabinoid signalling in Alzheimer’s disease
Mulder, J., Zilberter, M. Y., Pasquaré, S. J., Alpár, A., Schulte, G., Ferreira, S. G., Köfalvi, A., Martín-Moreno, A. M., Keimpema, E., Tanila, H., et al. (2011) · Brain · doi:10.1093/brain/awr046 · Cited by 211
Sarell, C. J., Syme, C. D., Rigby, S. E. J., & Viles, J. H. (2009) · Biochemistry · doi:10.1021/bi900254n · Cited by 209
Cuadrado‐Tejedor, M., Hervías, I., Ricobaraza, A., Puerta, E., Pérez-Roldán, J., García, C., Franco, R., Aguirre, N., & García‐Osta, A. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01517.x · Cited by 209
Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease
Baker‐Nigh, A., Vahedi, S., Davis, E., Weıntraub, S., Bigio, E. H., Klein, W. L., & Geula, C. (2015) · Brain · doi:10.1093/brain/awv024 · Cited by 211
Self-citationCalcium/calmodulin-dependent kinase II and Alzheimer’s disease
Ghosh, A., & Giese, K. P. (2015) · Molecular Brain · doi:10.1186/s13041-015-0166-2 · Cited by 205
Co-Localization of Amyloid Beta and Tau Pathology in Alzheimer's Disease Synaptosomes
Fein, J. A., Sokolow, S., Miller, C. A., Vinters, H. V., Yang, F., Cole, G. M., & Gylys, K. H. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070829 · Cited by 218
Tchantchou, F., Xu, Y., Wu, Y., Christen, Y., & Luo, Y. (2007) · The FASEB Journal · doi:10.1096/fj.06-7649com · Cited by 203
Calcium dysregulation in Alzheimer's disease
Bojarski, Ł., Herms, J. W., & Kuźnicki, J. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.10.002 · Cited by 207
Fu, A. K. Y., Hung, K.-W., Huang, H., Gu, S., Shen, Y., Cheng, E. Y. L., Ip, F. C. F., Huang, X., Fu, W.-Y., & Ip, N. Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405803111 · Cited by 201
Wnt-5a/JNK Signaling Promotes the Clustering of PSD-95 in Hippocampal Neurons
Farı́as, G. G., Alfaro, I. E., Cerpa, W. F., Grabowski, C. P., Godoy, J. A., Bonansco, C., & Inestrosa, N. C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808986200 · Cited by 205
Sarell, C. J., Wilkinson, S. R., & Viles, J. H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.171355 · Cited by 199
Petratos, S., Li, Q.-X., George, A. J., Hou, X., Kerr, M. L., Unabia, S. E., Hatzinisiriou, I., Maksel, D., Aguilar, M.-I., & Small, D. H. (2008) · Brain · doi:10.1093/brain/awm260 · Cited by 197
Adverse Stress, Hippocampal Networks, and Alzheimer’s Disease
Rothman, S. M., & Mattson, M. P. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8107-9 · Cited by 206
Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease
Viola, K. L., Sbarboro, J., Sureka, R., De, M., Bicca, M. A., Wang, J., Vasavada, S. R., Satpathy, S., Wu, S., Joshi, H. M., et al. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.254 · Cited by 196
Self-citationGralle, M., & Ferreira, S. T. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.02.001 · Cited by 202
Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190
Self-citationJiménez, S., Torres, M., Vizuete, M., Sanchez-Varo, R. M., Sánchez‐Mejías, E., Trujillo‐Estrada, L., Carmona‐Cuenca, I., Caballero, C., Ruano, D., Gutiérrez, A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209718 · Cited by 190
Impaired Spine Stability Underlies Plaque-Related Spine Loss in an Alzheimer's Disease Mouse Model
Spires-Jones, T. L., Meyer-Luehmann, M., Osetek, J. D., Jones, P. B., Stern, E. A., Bacskai, B. J., & Hyman, B. T. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070055 · Cited by 189
Zhao, W.-Q., Santini, F., Breese, R., Ross, D., Zhang, X. D., Stone, D. J., Ferrer, M., Townsend, M., Wolfe, A. L., Seager, M. A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.057182 · Cited by 188
Cotman, C. W., & Head, E. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15413 · Cited by 197
Synapse-Associated Protein-97 Mediates α-Secretase ADAM10 Trafficking and Promotes Its Activity
Marcello, E. E., Gardoni, F., Mauceri, D., Romorini, S., Jeromin, A., Epis, R., Borroni, B., Cattabeni, F., Sala, C., Padovani, A., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3439-06.2007 · Cited by 197
Wnt Signaling: Role in Alzheimer Disease and Schizophrenia
Inestrosa, N. C., Montecinos-Oliva, C., & Fuenzalida, M. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9417-5 · Cited by 192
A Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid
Savage, M. J., Kalinina, J., Wolfe, A. L., Tugusheva, K., Korn, R., Cash-Mason, T., Maxwell, J. W., Hatcher, N. G., Haugabook, S. J., Wu, G., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1675-13.2014 · Cited by 187
Garzon, D. J., & Fahnestock, M. L. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5053-06.2007 · Cited by 182
Kumar, S., & Walter, J. (2011) · Aging · doi:10.18632/aging.100362 · Cited by 191
Figueiredo, C. P., Clarke, J. R., Ledo, J. H., Ribeiro, F. C., Costa, C., Melo, H. M., Mota-Sales, A. P., Saraiva, L. M., Klein, W. L., Sebollela, A. S., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0482-13.2013 · Cited by 186
Self-citationSolution State Characterization of Amyloid β-Derived Diffusible Ligands
Hepler, R. W., Grimm, K. M., Nahas, D. D., Breese, R., Chen-Dodson, E., Acton, P. J., Keller, P. M., Yeager, M. D., Wang, H., Shughrue, P. J., et al. (2006) · Biochemistry · doi:10.1021/bi061850f · Cited by 182
Izzo, N. J., Staniszewski, A., To, L., Fa, M., Teich, A. F., Saeed, F., Wostein, H., Walko, T., Vaswani, A., Wardius, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111898 · Cited by 180
Hoey, S. E., Williams, R. J., & Perkinton, M. S. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.6017-08.2009 · Cited by 178
Aβ Toxicity in Alzheimer's Disease
Cavallucci, V., D’Amelio, M., & Cecconi, F. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8251-3 · Cited by 179
Transthyretin and familial amyloidotic polyneuropathy
Hou, X., Aguilar, M., & Small, D. H. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05712.x · Cited by 178
Lunardi, N., Ori, C., Erişir, A., & Jevtović‐Todorović, V. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9088-z · Cited by 179
Li, J., Kanekiyo, T., Shinohara, M., Zhang, Y., LaDu, M. J., Xu, H., & Bu, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.420224 · Cited by 179
Stefani, M. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.002 · Cited by 175
NELSON, R., GUO, Z., HALAGAPPA, V, PEARSON, M., GRAY, A., MATSUOKA, Y., BROWN, M., MARTIN, B., IYUN, T., & MAUDSLEY, S. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.01.037 · Cited by 173
Noguchi, A., Matsumura, S., Dezawa, M., Tada, M., Yanazawa, M., Ito, A., Akioka, M., Kikuchi, S., Sato, M., Ideno, S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000208 · Cited by 173
Pereira Diniz, L., Tortelli, V., Matias, I., Morgado, J., Bérgamo Araujo, A. P., Melo, H. M., Seixas da Silva, G. S., Alves-Leon, S. V., de Souza, J. M., Ferreira, S. T., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3351-16.2017 · Cited by 171
Bae, J. B., Lee, S., Jung, W., Park, S., Kim, W., Oh, H., Han, J. W., Kim, G. E., Kim, J. S., Kim, J. H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-79243-9 · Cited by 171
Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease
Paula‐Lima, A. C., Brito‐Moreira, J., & Ferreira, S. T. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12304 · Cited by 170
Insight into Amyloid Structure Using Chemical Probes
Reinke, A. A., & Gestwicki, J. E. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01110.x · Cited by 173
Caglayan, S., Takagi-Niidome, S., Liao, F., Carlo, A.-S., Schmidt, V., Burgert, T., Kitago, Y., Füchtbauer, E.-M., Füchtbauer, A., Holtzman, D. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007747 · Cited by 166
Broersen, K., Rousseau, F., & Schymkowitz, J. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt36 · Cited by 168
Tapia‐Rojas, C., Aránguiz, F. C., Varela‐Nallar, L., & Inestrosa, N. C. (2015) · Brain Pathology · doi:10.1111/bpa.12255 · Cited by 176
Cytoskeletal pathologies of Alzheimer disease
Bamburg, J. R., & Bloom, G. S. (2009) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.20388 · Cited by 175
Decker, H., Jürgensen, S., Adrover, M. F., Brito‐Moreira, J., Bomfim, T. R., Klein, W. L., Epstein, A. L., Felice, F. G. D., Jerusalinsky, D. A., & Ferreira, S. T. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07058.x · Cited by 172
Self-citationRammes, G., Hasenjäger, A., Sroka-Saidi, K., Deussing, J. M., & Parsons, C. G. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.051 · Cited by 163
Tchantchou, F., Lacor, P. N., Cao, Z., Lao, L., Hou, Y., Cui, C., Klein, W. L., & Luo, Y. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1189 · Cited by 164
Self-citationGoody, S. M. G., Baum, M. L., Paspalas, C. D., Fernandez, S. M., Carty, N., Kurup, P. K., & Lombroso, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003053 · Cited by 162
Self-citationCrimins, J. L., Pooler, A. M., Polydoro, M., Luebke, J. I., & Spires‐Jones, T. L. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.03.002 · Cited by 173
Fujita, K., Motoki, K., Tagawa, K., Chen, X., Hama, H., Nakajima, K., Homma, H., Tamura, T., Watanabe, H., Katsuno, M., et al. (2016) · Scientific Reports · doi:10.1038/srep31895 · Cited by 160
Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s Disease
Wilcox, K. C., Lacor, P. N., Pitt, J. E., & Klein, W. L. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9691-4 · Cited by 159
Self-citationViayna, E., Sola, I., Bartolini, M., Simone, A. D., Tapia‐Rojas, C., Serrano, F. G., Sabaté, R., Juárez‐Jiménez, J., Pérez, B., Luque, F. J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401824w · Cited by 156
GluT4: A central player in hippocampal memory and brain insulin resistance
McNay, E. C., & Pearson-Leary, J. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113076 · Cited by 159
AMPA receptors as drug targets in neurological disease—advantages, caveats, and future outlook
Chang, P. K. ‐., Verbich, D., & McKinney, R. A. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08165.x · Cited by 155
Peroxisomal Proliferation Protects from β-Amyloid Neurodegeneration
Santos, M. J., Quintanilla, R. A., Toro, A., Grandy, R. A., Dinamarca, M. C., Godoy, J. A., & Inestrosa, N. C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505160200 · Cited by 155
Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ
Zhao, W.-Q., Lacor, P. N., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.011015 · Cited by 154
Self-citationWang, Z., Jackson, R. J., Hong, W., Taylor, W. M., Corbett, G. T., Moreno, A. J., Liu, W., Li, S., Frosch, M. P., Slutsky, I., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.2009-17.2017 · Cited by 157
Reelin signaling antagonizes β-amyloid at the synapse
Durakoglugil, M. S., Chen, Y., White, C. L., Kavalali, E. T., & Herz, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908176106 · Cited by 153
Alzheimer’s disease: How metal ions define β-amyloid function
Kepp, K. P. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.007 · Cited by 154
Alifragis, P., & Marsh, J. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.230276 · Cited by 156
Positioning of the Alzheimer Aβ(1–40) peptide in SDS micelles using NMR and paramagnetic probes
Jarvet, J., Danielsson, J., Damberg, P., Oleszczuk, M., & Gräslund, A. (2007) · Journal of Biomolecular NMR · doi:10.1007/s10858-007-9176-4 · Cited by 151
NMDA and AMPA receptors dysregulation in Alzheimer's disease
Babaei, P. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174310 · Cited by 155
Nazem, A., & Mansoori, G. A. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13210 · Cited by 150
Ardiles, Á. O., Tapia‐Rojas, C., Mandal, M., Alexandre, F., Kirkwood, A., Inestrosa, N. C., & Palacios, A. G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201209109 · Cited by 152
Amyloid β oligomers (AβOs) in Alzheimer’s disease
Mroczko, B., Groblewska, M., Litman‐Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1820-x · Cited by 150
Peters, D. G., Connor, J. R., & Meadowcroft, M. D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.007 · Cited by 146
Advances in Alzheimer’s Diagnosis and Therapy: The Implications of Nanotechnology
Hajipour, M. J., Santoso, M. R., Rezaee, F., Aghaverdi, H., Mahmoudi, M., & Perry, G. L. (2017) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.06.002 · Cited by 144
Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer's disease
Ma, K., & Qian, Y. (2018) · Neuropeptides · doi:10.1016/j.npep.2018.12.003 · Cited by 147
Klein, W. L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129039 · Cited by 145
Self-citationFine structure study of Aβ 1–42 fibrillogenesis with atomic force microscopy
Arimon, M., Díez‐Pérez, I., Kogan, M. J., Durany, N., Giralt, E., Sanz, F., & Fernàndez‐Busquets, X. (2005) · The FASEB Journal · doi:10.1096/fj.04-3137fje · Cited by 141
Brain cholinergic vulnerability: Relevance to behavior and disease
McKinney, M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.05.019 · Cited by 140
Ostapchenko, V. G., Chen, M., Guzmán, M. S., Xie, Y., Lavine, N. E., Fan, J., Beraldo, F. H., Martyn, A. C., Belrose, J. C., Mori, Y., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4081-14.2015 · Cited by 143
Garcia, P., Youssef, I., Utvik, J. K., Florent-Béchard, S., Barthélémy, V., Malaplate-Armand, C., Kriem, B., Stenger, C., Koziel, V., Olivier, J.-L., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4182-09.2010 · Cited by 139
Nimmrich, V., & Ebert, U. (2009) · Reviews in the Neurosciences · doi:10.1515/revneuro.2009.20.1.1 · Cited by 139
Gralle, M., Caarls, M. B., & Wouters, F. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808755200 · Cited by 148
Meilandt, W. J., Cissé, M., Ho, K., Wu, T. Z., Esposito, L., Scearce-Levie, K. A., Cheng, I. H.-J., Yu, G.-Q., & Mucke, L. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.2984-08.2009 · Cited by 144
Site-Specific Blockade of RAGE-VdPrevents Amyloid-β Oligomer Neurotoxicity
Sturchler, E., Galichet, A., Weibel, M., Leclerc, E., & Heizmann, C. W. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4878-07.2008 · Cited by 136
Molecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimer׳s disease
Lloret, A., Fuchsberger, T., Giraldo, E., & Viña, J. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.02.028 · Cited by 135
Pitt, J., Roth, W., Lacor, P., Smith, A. B., Blankenship, M., Velasco, P., De Felice, F., Breslin, P., & Klein, W. L. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.018 · Cited by 134
Self-citationThal, D. R., Griffin, W. S. T., & Braak, H. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00411.x · Cited by 134
Collagen VI protects neurons against Aβ toxicity
Cheng, J. S., Dubal, D. B., Kim, D. H., Legleiter, J. A., Cheng, I. H.-J., Yu, G.-Q., Tesseur, I. C., Wyss‐Coray, T., Bonaldo, P., & Mucke, L. (2009) · Nature Neuroscience · doi:10.1038/nn.2240 · Cited by 145
Cholesterol in Alzheimers Disease: Unresolved Questions
Stefani, M., & Liguri, G. (2009) · Current Alzheimer Research · doi:10.2174/156720509787313899 · Cited by 136
Carrero, I., Gonzalo, M. R., Martin, B., Sanz-Anquela, J. M., Arévalo-Serrano, J., & Gonzalo-Ruiz, A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.05.004 · Cited by 132
Shaked, G. M., Kummer, M. P., Lu, D. C., Galvan, V., Bredesen, D. E., Koo, E. H., Shaked, G. M., Kummer, M. P., Lu, D. C., Galvan, V., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-5032fje · Cited by 132
Synaptic remodeling during aging and in Alzheimer's disease
Masliah, E., Crews, L., & Hansen, L. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s311 · Cited by 132
New developments on the role of NMDA receptors in Alzheimer's disease
Malinow, R. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.09.001 · Cited by 132
PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131
Hamilton, A., Esseltine, J. L., DeVries, R. A., Cregan, S. P., & Ferguson, S. S. G. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-40 · Cited by 138
Maloney, M. T., Minamide, L. S., Kinley, A. W., Boyle, J. A., & Bamburg, J. R. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3711-05.2005 · Cited by 140
p21-activated Kinase-aberrant Activation and Translocation in Alzheimer Disease Pathogenesis
Ma, Q., Yang, F., Calon, F., Ubeda, O. J., Hansen, J. E., Weisbart, R. H., Beech, W. K., Frautschy, S. A., & Cole, G. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708034200 · Cited by 131
The role of copper ions in pathophysiology and fluorescent sensors for the detection thereof
Verwilst, P., Sunwoo, K., & Kim, J. S. (2015) · Chemical Communications · doi:10.1039/c4cc10366a · Cited by 133
Cdk5: Multitasking between physiological and pathological conditions
Lopes, J. P., & Agostinho, P. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.03.006 · Cited by 134
Variations in the neuropathology of familial Alzheimer’s disease
Shepherd, C. E., McCann, H., & Halliday, G. M. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0521-4 · Cited by 135
Metadata
- Authors
- Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., Krafft, G. A., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- University of Southern California (US)
- Acumen Pharmaceuticals (United States) (US)
- Corresponding author
- Klein, William L.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2004-11-10
- Volume
- 24
- Issue
- 45
- Pages
- 10191-10200
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6730194
- OpenAlex
- W2162807572
- Cited by
- 954
- References
- 64
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 24 · 2023: 41 · 2022: 35 · 2021: 28 · 2020: 26 · 2019: 32 · 2018: 41 · 2017: 50 · 2016: 51 · 2015: 50 · 2014: 54 · 2013: 65 · 2012: 59
- FWCI
- 25.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Illinois Department of Public Health
- Northwestern University
- National Institutes of Health (AG11385)
- National Institute on Aging (R01 AG11385, P30AG13854, R01AG022547, R01-AG22547, R01AG011385, R03AG022237, R01-AG18877, P30AG013854, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, synaptic targeting, long-term potentiation, synaptic plasticity, PSD-95, Arc, hippocampal neurons, memory loss, early Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Animals, Binding Sites, Cerebral Cortex, Cerebrospinal Fluid Proteins, Chromatography, High Pressure Liquid, Cytoskeletal Proteins, Female, Hippocampus, Humans, Male, Nerve Tissue Proteins, Neurons, Peptide Fragments, Protein Binding, Synapses, Tissue Extracts, Amyloid beta-Peptides, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
